CN101389655B - 新的hcdr3区域集合及其应用 - Google Patents
新的hcdr3区域集合及其应用 Download PDFInfo
- Publication number
- CN101389655B CN101389655B CN2006800530247A CN200680053024A CN101389655B CN 101389655 B CN101389655 B CN 101389655B CN 2006800530247 A CN2006800530247 A CN 2006800530247A CN 200680053024 A CN200680053024 A CN 200680053024A CN 101389655 B CN101389655 B CN 101389655B
- Authority
- CN
- China
- Prior art keywords
- amino acid
- cdr3
- approximately
- diversified
- zone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001413 amino acids Chemical class 0.000 claims abstract description 440
- 239000012634 fragment Substances 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 14
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 13
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 13
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 22
- 125000000539 amino acid group Chemical group 0.000 claims description 19
- 108020004414 DNA Proteins 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 17
- 239000002131 composite material Substances 0.000 claims description 7
- 102000053602 DNA Human genes 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 12
- 238000005516 engineering process Methods 0.000 abstract description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 4
- 238000002703 mutagenesis Methods 0.000 abstract description 2
- 231100000350 mutagenesis Toxicity 0.000 abstract description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 423
- 229940024606 amino acid Drugs 0.000 description 421
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 30
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 25
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 25
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 22
- 235000003704 aspartic acid Nutrition 0.000 description 15
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 12
- 239000004471 Glycine Substances 0.000 description 11
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 8
- 150000001510 aspartic acids Chemical class 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 108091035707 Consensus sequence Proteins 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 239000004473 Threonine Substances 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 235000008729 phenylalanine Nutrition 0.000 description 4
- 241000894007 species Species 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical class CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- -1 aromatic amino acid Chemical class 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 150000002994 phenylalanines Chemical class 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 206010060935 Alloimmunisation Diseases 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009432 framing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (7)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75163305P | 2005-12-20 | 2005-12-20 | |
US60/751,633 | 2005-12-20 | ||
PCT/IB2006/004301 WO2008053275A2 (en) | 2005-12-20 | 2006-12-15 | Novel collection of hcdr3 regions and uses therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101389655A CN101389655A (zh) | 2009-03-18 |
CN101389655B true CN101389655B (zh) | 2013-05-22 |
Family
ID=39273832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800530247A Active CN101389655B (zh) | 2005-12-20 | 2006-12-15 | 新的hcdr3区域集合及其应用 |
Country Status (15)
Country | Link |
---|---|
US (1) | US8273688B2 (zh) |
EP (1) | EP1979378B1 (zh) |
JP (1) | JP5405831B2 (zh) |
KR (1) | KR20080080653A (zh) |
CN (1) | CN101389655B (zh) |
AU (1) | AU2006350452B2 (zh) |
CA (1) | CA2634387C (zh) |
DK (1) | DK1979378T3 (zh) |
ES (1) | ES2394722T3 (zh) |
IL (1) | IL192315A0 (zh) |
MX (1) | MX2008008220A (zh) |
NO (1) | NO20083171L (zh) |
NZ (1) | NZ569359A (zh) |
WO (1) | WO2008053275A2 (zh) |
ZA (1) | ZA200806016B (zh) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
EP1912675B1 (en) * | 2005-07-25 | 2014-02-12 | Emergent Product Development Seattle, LLC | B-cell reduction using cd37-specific and cd20-specific binding molecules |
US8409577B2 (en) * | 2006-06-12 | 2013-04-02 | Emergent Product Development Seattle, Llc | Single chain multivalent binding proteins with effector function |
MX344415B (es) | 2007-09-14 | 2016-12-15 | Adimab Inc | Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos. |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
EP2098536A1 (en) | 2008-03-05 | 2009-09-09 | 4-Antibody AG | Isolation and identification of antigen- or ligand-specific binding proteins |
US9873957B2 (en) | 2008-03-13 | 2018-01-23 | Dyax Corp. | Libraries of genetic packages comprising novel HC CDR3 designs |
JP6013733B2 (ja) * | 2008-04-11 | 2016-10-25 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | Cd37免疫治療薬および二機能性化学療法薬とのその組合せ |
WO2009132287A2 (en) * | 2008-04-24 | 2009-10-29 | Dyax Corp. | Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs |
NZ596603A (en) | 2009-05-29 | 2013-07-26 | Morphosys Ag | A collection of antibodies or fragments having properties relevant to developability |
US20110082054A1 (en) * | 2009-09-14 | 2011-04-07 | Dyax Corp. | Libraries of genetic packages comprising novel hc cdr3 designs |
KR102318383B1 (ko) | 2010-07-16 | 2021-10-27 | 아디맵 엘엘씨 | 항체 라이브러리 |
WO2012066129A1 (en) | 2010-11-19 | 2012-05-24 | Morphosys Ag | A collection and methods for its use |
KR20180053322A (ko) | 2015-09-21 | 2018-05-21 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Cd3 결합 폴리펩타이드 |
CN105274630A (zh) * | 2015-11-25 | 2016-01-27 | 苏州泓迅生物科技有限公司 | 基于组合合成技术合成可控的人源化抗体库的方法与应用 |
WO2017125871A1 (en) * | 2016-01-19 | 2017-07-27 | Zumutor Biologics, Inc. | A method of generating a synthetic antibody library, said library and application(s) thereof |
EP3293293A1 (en) | 2016-09-08 | 2018-03-14 | Italfarmaco SpA | Hc-cdr3-only libraries with reduced combinatorial redundancy and optimized loop length distribution |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6828422B1 (en) * | 1995-08-18 | 2004-12-07 | Morphosys Ag | Protein/(poly)peptide libraries |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2229043C (en) * | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
ATE417925T1 (de) * | 1999-07-20 | 2009-01-15 | Morphosys Ag | Verfahren zur präsentation von (poly)peptiden/proteinen auf bakteriophagenpartikeln via disulfidbindungen |
ES2360479T3 (es) * | 2000-12-18 | 2011-06-06 | Dyax Corp. | Bibliotecas focalizadas de paquetes genéticos. |
-
2006
- 2006-12-15 NZ NZ569359A patent/NZ569359A/en unknown
- 2006-12-15 KR KR1020087017753A patent/KR20080080653A/ko not_active Application Discontinuation
- 2006-12-15 CN CN2006800530247A patent/CN101389655B/zh active Active
- 2006-12-15 AU AU2006350452A patent/AU2006350452B2/en active Active
- 2006-12-15 CA CA2634387A patent/CA2634387C/en active Active
- 2006-12-15 DK DK06851829.9T patent/DK1979378T3/da active
- 2006-12-15 ES ES06851829T patent/ES2394722T3/es active Active
- 2006-12-15 MX MX2008008220A patent/MX2008008220A/es not_active Application Discontinuation
- 2006-12-15 EP EP06851829A patent/EP1979378B1/en active Active
- 2006-12-15 US US12/158,181 patent/US8273688B2/en active Active
- 2006-12-15 JP JP2008546696A patent/JP5405831B2/ja active Active
- 2006-12-15 WO PCT/IB2006/004301 patent/WO2008053275A2/en active Application Filing
-
2008
- 2008-06-19 IL IL192315A patent/IL192315A0/en unknown
- 2008-07-10 ZA ZA200806016A patent/ZA200806016B/xx unknown
- 2008-07-18 NO NO20083171A patent/NO20083171L/no not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6828422B1 (en) * | 1995-08-18 | 2004-12-07 | Morphosys Ag | Protein/(poly)peptide libraries |
Non-Patent Citations (4)
Title |
---|
Achim Knappik et al.Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides.《J.Mol.Biol》.2000,第296卷摘要、第69页右栏第2段,第72页右栏第3段至73页右栏第3段. * |
Chingwei V. Lee et al.High-affinity Human Antibodies from Phage-displayed Synthetic Fab Libraries with a Single Framework Scaffold.《J. Mol. Biol》.2004,第340卷摘要、第1088页右栏第22-27行. * |
Michael zemlin et al.Expressed Murine and Human CDR-H3 Intervals of Equal Length Exhibit Distinct Repertoires that Differ in their Amino Acid Composition and Predicted Range of Structures.《J. Mol. Biol》.2003,第334卷全文. * |
Yvelise Barrios et al.Length of the antibody heavy chain complementarity determining region 3 as a specificity-determining factor.《JOURNAL OF MOLECULAR RECOGNITION》.2004,第17卷全文. * |
Also Published As
Publication number | Publication date |
---|---|
JP5405831B2 (ja) | 2014-02-05 |
MX2008008220A (es) | 2009-03-04 |
ZA200806016B (en) | 2009-07-29 |
DK1979378T3 (da) | 2012-10-29 |
CN101389655A (zh) | 2009-03-18 |
KR20080080653A (ko) | 2008-09-04 |
AU2006350452B2 (en) | 2012-10-25 |
CA2634387C (en) | 2015-11-24 |
EP1979378B1 (en) | 2012-07-25 |
NO20083171L (no) | 2008-08-27 |
US20090088346A1 (en) | 2009-04-02 |
ES2394722T3 (es) | 2013-02-05 |
IL192315A0 (en) | 2008-12-29 |
WO2008053275A3 (en) | 2008-08-21 |
AU2006350452A1 (en) | 2008-05-08 |
US8273688B2 (en) | 2012-09-25 |
NZ569359A (en) | 2011-11-25 |
JP2009519727A (ja) | 2009-05-21 |
EP1979378A2 (en) | 2008-10-15 |
WO2008053275A2 (en) | 2008-05-08 |
CA2634387A1 (en) | 2008-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101389655B (zh) | 新的hcdr3区域集合及其应用 | |
JP2009519727A5 (zh) | ||
CA2572961C (en) | Universal antibody libraries | |
MXPA05000511A (es) | Anticuepros super humanizados. | |
CN102858800A (zh) | 人源化抗体 | |
US20090082213A1 (en) | Construction of diverse synthetic peptide and polypeptide libraries | |
EP2347038A1 (en) | Methods of humanizing and affinity-maturing antibodies | |
CN107739405A (zh) | 骆驼科动物来源的抗原结合多肽 | |
CA2312208A1 (en) | Humanization of murine antibody | |
WO2005079479A3 (en) | Super-humanized antibodies against respiratory syncytial virus | |
WO2003050531A3 (en) | Method for displaying loops from immunoglobulin domains in different contexts | |
CN105017427A (zh) | 修饰抗体的方法和具有改善的功能性质的修饰抗体 | |
JP2009515516A (ja) | 推定成熟cdrのブラスティングならびにコホートライブラリの作製およびスクリーニングによる抗体の超ヒト化 | |
Kuroda et al. | Systematic classification of CDR‐L3 in antibodies: implications of the light chain subtypes and the VL–VH interface | |
Honegger et al. | The influence of the buried glutamine or glutamate residue in position 6 on the structure of immunoglobulin variable domains | |
Baek et al. | Humanization of a phosphothreonine peptide-specific chicken antibody by combinatorial library optimization of the phosphoepitope-binding motif | |
JP2005512962A5 (zh) | ||
CN106574270A (zh) | 多肽表达系统 | |
US20090318308A1 (en) | Highly diversified antibody libraries | |
JP6974909B2 (ja) | 減少したコンビナトリアル冗長性及び最適化ループ長分布を有するhc−cdr3のみのライブラリー | |
Yin et al. | Construction of a Fully Synthetic Human scFv Antibody Library with CDR3 Regions Randomized by a Split–Mix–Split Method and Its Application | |
CA2859498A1 (en) | Advertisement providing apparatus and method for providing advertisements | |
AU2014200954B2 (en) | Design and construction of diverse synthetic peptide and polypeptide libraries | |
Almagro et al. | Novel approaches in discovery and design of antibody-based therapeutics | |
Jermutus et al. | Tailored amino acid diversity for the evolution of antibody affinity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CI01 | Publication of corrected invention patent application |
Correction item: Inventor Correct: Stefanie Terry|Joseph Prasler False: Stefani Teljosef Plath le Number: 11 Page: 1021 Volume: 25 |
|
CI02 | Correction of invention patent application |
Correction item: Inventor Correct: Stefanie Terry|Joseph Prasler False: Stefani Teljosef Plath le Number: 11 Page: The title page Volume: 25 |
|
ERR | Gazette correction |
Free format text: CORRECT: INVENTOR; FROM: STEFANO TEERJOSEPH PLASLER - TO: STEFANI TEER - JOSEPH PULASLER |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1125952 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1125952 Country of ref document: HK |